Delamanid (DLM)

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Wuhan Pulmonary Hospital

Conditions

Treat to TargetTreatment DurationTuberculosis, MDR

Phase 3

Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Active, not recruitingNCT03568383

National Institute of Allergy and Infectious Diseases (NIAID)Tuberculosis, MDR

Start: 2019-06-03End: 2027-01-11Updated: 2025-06-15

Unknown Phase

6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province

Not yet recruitingNCT07198685

Wuhan Pulmonary HospitalTreatment Duration, Treat to Target

Start: 2025-09-30End: 2028-09-30Target: 52Updated: 2025-09-30

Related Papers

Update on multidrug-resistant tuberculosis preventive therapy toward the global tuberculosis elimination.

2025-02-229 citations